GET THE APP

INHIBITION OF PTPase PROTECTS AGAINST STRUCTURAL AND FUNCTIO | 58288

Internationale Zeitschrift für Angewandte Biologie und Pharmazeutische Technologie

Abstrakt

INHIBITION OF PTPase PROTECTS AGAINST STRUCTURAL AND FUNCTIONAL RENAL ABNORMALITIES IN EXPERIMENTAL MODEL OF CKD

GAGANDEEP KAUR,

Chronic kidney disease (CKD) a recognized predicament comprises
of renal fibrosis, inflammation, structural and functional
changes in kidney. Further, preclinical use of protein tyrosine
phosphatase inhibitor (sodium orthovanadate)/(SOV) to improve
mitochondrial enzyme activity and to accelerate angiogenesis in
diseased animals have also been registered in earlier studies. In the
present study, we investigated whether sodium orthovanadate will
be able to turn down bilateral I/R-induced CKD by suppressing
these renal alterations or not. Bilateral I/R surgery was performed
to induce chronic kidney disease in Wistar rats, which leads to
the development of severe tubulointerstitial fibrosis and glomerulosclerosis
with altered renal function. Noticeable changes were
observed in oxidative stress, serum and urine parameters after subsequent
SOV treatment (5mg and 10mg/kg/p.o) for 90 days in
CKD rats. Furthermore, SOV treatment showed beneficial effects
on mRNA expression of Kim-1, TGF-β and Collagen-IV, which is
known to promote fibrosis via various signalling pathways involved
in the progression of renal disease, Additionally, results revealed
that SOV treatment successfully reduced the overexpression of
pro-inflammatory marker IL-6 and also helped to restore reduced
expression of nephrin, and podocin in bilateral I/R-induced
CKD animals. Moreover, present studies also demonstrated the
considerable functional and structural changes after SOV treatment,
and these results are further supported via data obtained
from the biochemical analysis and quantitaive analysis of histopathological
slides respectively. In conclusion, SOV reduces renal
fibrosis,glomerulosclerosis and inflammation in chronic kidney
disease by modulating involved gene expressions (PTP-1B, IL-6,
podocin, nephrin,Kim-1, TGF-β and Collagen-IV)and inhibiting
PTPase activity in renal tissue.
Biography:
Gagandeep Kaur has her expertise in evaluation and passion
in improving the health and wellbeing. She is a Ph.D (Research
Scholar) working under the kind supervision of Dr. Pawan Krishan
in the department of Pharmaceutical Sciences and Drug Research,
Punjabi University, Patiala, Punjab (India). Currently, she

Haftungsausschluss: Diese Zusammenfassung wurde mithilfe von Tools der künstlichen Intelligenz übersetzt und wurde noch nicht überprüft oder verifiziert.